ARS Pharmaceuticals Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Great. Welcome back everyone to our next session. I'm Roanna Ruiz, Senior Biotech Analyst here at SVB Securities, and it's my pleasure to introduce the management team of ARS Pharmaceuticals.
First we have Richard Lowenthal, CEO; and Eric Karas, Chief Commercial Officer. So thanks both for joining us. And we're going to kick it off a little bit with some bigger picture questions. So maybe, could you just give us a brief overview of the company and your lead intranasal epinephrine product, neffy?
Yes. Thank you, Roanna. So we started ARS a number of years ago, really, with the explicit focus of developing needle-free nasal spray with epinephrine that can achieve injection-like levels, therapeutic levels of epinephrine to solve a lot of problems in the community.
And at the time, we are working on a number of other nasal spray products that we're proud to have been involved in and are on the market. And we're also working with the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |